NVCR (NovoCure Limited Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by NVCR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Michal Nath Puri | Chief Human Resources Officer | A | — | — |
| 2026-07-01 | Arye Barak Ben | General Counsel | A | — | — |
| 2026-07-01 | Frank X Leonard | Chief Executive Officer | A | — | — |
| 2026-07-01 | Asaf Danziger | Director | A | — | — |
| 2026-06-05 | Frank X Leonard | Chief Executive Officer | Sell | — | — |
| 2026-06-05 | Kristin Stafford | Director | A | — | — |
| 2026-06-05 | GABRIEL LEUNG | Director | A | — | — |
| 2026-06-05 | Timothy J Scannell | Director | A | — | — |
| 2026-06-05 | W ANTHONY VERNON | Director | A | — | — |
| 2026-06-05 | JERYL L HILLEMAN | Director | A | — | — |
| 2026-06-05 | Allyson J Ocean | Director | A | — | — |
| 2026-06-05 | Martin J. Madden | Director | A | — | — |
| 2026-06-05 | David Hung | Director | A | — | — |
| 2026-06-03 | Timothy J Scannell | Director | Sell | — | — |
| 2026-06-03 | David Hung | Director | Sell | — | — |
| 2026-06-03 | GABRIEL LEUNG | Director | Sell | — | — |
| 2026-06-03 | JERYL L HILLEMAN | Director | Sell | — | — |
| 2026-06-03 | Kristin Stafford | Director | Sell | — | — |
| 2026-06-03 | Allyson J Ocean | Director | Sell | — | — |
| 2026-06-03 | W ANTHONY VERNON | Director | Sell | — | — |
| 2026-04-28 | W ANTHONY VERNON | Director | M | — | — |
| 2026-03-05 | Ashley Cordova | Former Chief Executive Officer | F | — | — |
| 2026-03-05 | Arye Barak Ben | General Counsel | A | — | — |
| 2026-03-05 | Christoph Brackmann | Chief Financial Officer | MIXED | — | — |
| 2026-03-05 | Uri Weinberg | Chf Medical and Innovation Ofr | MIXED | — | — |
| 2026-03-05 | Nicolas Leupin | Former Chief Medical Officer | Sell | — | — |
| 2026-03-05 | Mukund Paravasthu | Chief Operating Officer | MIXED | — | — |
| 2026-03-05 | Michal Nath Puri | Chief Human Resources Officer | MIXED | — | — |
| 2026-03-05 | WILLIAM F DOYLE | Executive Chairman | MIXED | — | — |
| 2026-03-05 | Frank X Leonard | Chief Executive Officer | MIXED | — | — |
| 2026-03-03 | Nicolas Leupin | Former Chief Medical Officer | Sell | — | — |
| 2026-03-03 | Mukund Paravasthu | Chief Operating Officer | Sell | — | — |
| 2026-03-03 | Arye Barak Ben | General Counsel | A | — | — |
| 2026-03-03 | Frank X Leonard | Chief Executive Officer | MIXED | — | — |
| 2026-03-03 | Michal Nath Puri | Chief Human Resources Officer | Sell | — | — |
| 2026-03-03 | Uri Weinberg | Chf Medical and Innovation Ofr | MIXED | — | — |
| 2026-03-03 | Ashley Cordova | Former Chief Executive Officer | MIXED | — | — |
| 2026-01-12 | Mukund Paravasthu | Chief Operating Officer | F | — | — |
| 2025-11-04 | Michal Nath Puri | Chief Human Resources Officer | F | — | — |
| 2025-11-04 | Frank X Leonard | EVP, Pres., Novocure Oncology | F | — | — |
| 2025-11-04 | Christoph Brackmann | Chief Financial Officer | F | — | — |
| 2025-11-04 | Mukund Paravasthu | Chief Operating Officer | F | — | — |
| 2025-09-08 | Ashley Cordova | Chief Executive Officer | Buy | — | — |
| 2025-07-30 | Christoph Brackmann | Chief Financial Officer | Buy | — | — |
| 2025-07-01 | Asaf Danziger | Director | A | — | — |
| 2025-07-01 | Michal Nath Puri | Chief Human Resources Officer | A | — | — |
| 2025-07-01 | Frank X Leonard | EVP, Pres., Novocure Oncology | A | — | — |
| 2025-07-01 | Ashley Cordova | Chief Executive Officer | A | — | — |
| 2025-07-01 | Arye Barak Ben | General Counsel | A | — | — |
| 2025-06-06 | Frank X Leonard | EVP, Pres., Novocure Oncology | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 19,006,064 | — |
| — | Director | 14,018,365 | — |
| — | 10%+ Owner | 9,780,397 | — |
| — | 10%+ Owner | 7,216,789 | — |
| — | 10%+ Owner | 2,741,925 | — |
| — | Chief Technology Officer | 1,041,054 | — |
| — | Executive Chairman | 766,564 | — |
| — | Chief Executive Officer | 461,425 | — |
| — | Former Chief Executive Officer | 422,570 | — |
| — | Chief Executive Officer | 416,742 | — |
| — | Chief Operating Officer | 376,663 | — |
| — | Chf Medical and Innovation Ofr | 267,190 | — |
| — | General Counsel | 243,752 | — |
| — | Chief Operating Officer | 238,042 | — |
| — | Director | 209,267 | — |
| — | Chief Human Resources Officer | 203,227 | — |
| — | Chief Financial Officer | 182,842 | — |
| — | Director | 168,114 | — |
| — | Chief Science Officer | 152,408 | — |
| — | Chief Growth Officer | 124,511 | — |
| — | Chief Operating Officer | 121,455 | — |
| — | Former Chief Medical Officer | 102,979 | — |
| — | Director | 101,109 | — |
| — | Director | 71,764 | — |
| — | Chief Science Officer | 69,771 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NVCR quote page; the site-wide leaderboard is on the insider transactions hub.